B+
Bull case
25%
Probability
Target price
$1.00
+36.9% vs current
BFRG
BullFrog AICNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.55
-24.7% vs current
B-
Bear case
30%
Probability
Target price
$0.30
-58.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+27.6
Score
AI commentary
Primary evidence supports a cautious monitoring view rather than a bullish thesis change. The April 22, 2026 8-K removes an immediate Nasdaq-compliance overhang, but the more decision-relevant 10-K evidence remains negative on runway and operating scale. Recent packet news is thin and not thesis-forming, no reliable analyst-target set is available, and social coverage is absent, so confidence should stay low.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-22eventNasdaq equity compliance regained but must be sustainedHigh impact
BullFrog disclosed on April 22, 2026 that Nasdaq notified the company it had regained compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), removing an immediate listing overhang but not the broader execution and financing burden for a micro-cap issuer [#8-K-2026-04-22].
2026-07-31catalystFinancing and runway update remains the key near-term swing factorHigh impact
The 2025 10-K states the company had about $2.3 million of cash at December 31, 2025, had an accumulated deficit of about $23.3 million, and believed existing cash would not be sufficient to fund planned operations for at least one year beyond the filing date; any financing update could dominate near-term equity performance [#10-K-2026-03-19].
2026-12-31catalystCommercial follow-through beyond the Eleison collaborationHigh impact
The 2025 10-K says BullFrog recognized about $117,000 of 2025 collaboration revenue, entirely from its lone Eleison Pharmaceuticals agreement, and says it plans to offer the BullFrog Data Networks solution to other biotech and pharma customers; any additional paid deployments would matter disproportionately at the current scale [#10-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology